🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — March 06, 2026

This period's $6.6B in significant contract modifications is dominated by a $2.87B NASA award to Lockheed Martin for space vehicle components, signaling sustained aerospace demand despite historical dates and zero outlays across many contracts. Bullish signals prevail (16/20) in emerging nuclear (HALEU at $900M to General Matter), healthcare IT (Optum $724M VA, GD IT $146M CMS), and federal IT services, with options adding $2B+ potential upside. Risks center on execution delays ($0 outlays common), firm-fixed-price margin pressures, and ended performance periods limiting near-term cash flows.

20 total filings
· daily

Contract Deobligations Alert — March 06, 2026

This $6.6B batch of contract obligations is dominated by a single $2.87B legacy NASA award to Lockheed Martin for space vehicle components, signaling sustained but historical demand in aerospace. Bullish signals prevail (16/20) across IT/services, healthcare, and emerging nuclear energy (HALEU), with multi-year revenues and $2B+ in unexercised options offering upside. Risks center on $0 outlays (prevalent in 70%+ of records) and firm-fixed-price structures exposing contractors to cost overruns amid long performance periods.

20 total filings
· daily

Contract Option Exercises — March 06, 2026

This week's contract exercises reveal $6.6B in obligations dominated by legacy NASA space contracts (e.g., Lockheed Martin $2.87B), signaling sustained U.S. space investment despite historical end dates and $0 outlays. Emerging bullish signals in nuclear fuel (General Matter $900M HALEU) and healthcare IT (Optum $724M VA, General Dynamics $146M HHS) highlight sector growth, with 16/20 bullish amid options upside totaling billions. Risks center on $0 outlays (12 contracts) and firm-fixed-price exposures, but long-term periods to 2041 offer multi-year revenue visibility for primes like Leidos, ManTech, and Deloitte.

20 total filings
· daily

All DOE Contracts — March 06, 2026

General Matter, Inc., a small business, secured a $900M DOE contract (potential $1.135B with options) for domestic HALEU UF6 production capacity, signaling strong U.S. government commitment to advanced nuclear fuels over a 10-year horizon. This positions the company for long-term revenue but carries execution risks under a firm fixed-price structure with no outlays to date. Investors should monitor HALEU sector for supply chain buildup amid nuclear energy resurgence.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — March 06, 2026

This $6.08B batch of mega contracts is dominated by Lockheed Martin's $2.87B NASA space vehicle award (47% of total), underscoring persistent U.S. space spending despite historical timelines. Emerging bullish signals in nuclear energy via General Matter's $900M DOE HALEU production deal and healthcare IT via Optum's $724M VA order highlight growth in strategic sectors. IT/defense primes like Leidos, ManTech, Palantir show $600M+ obligations with $1.4B options potential, though $0 outlays across most signal funding lags; prioritize monitoring option exercises for 50%+ upside.

12 total filings
· daily

High-Value Federal Grants ($5M+) — March 06, 2026

This $6.62B batch of 19 high-value federal contracts (> $5M) yields 16 bullish signals, dominated by legacy NASA space awards to primes like Lockheed Martin ($2.87B) and emerging nuclear energy production (General Matter $900M HALEU). IT/telecom and healthcare services for VA/HHS/DHS show strong multi-year visibility with partial outlays, while firm-fixed pricing and $0 outlays in 12 contracts flag execution risks. Investors should prioritize options upside (~$3B+ potential) in active IT/healthcare deals over historical NASA obligations.

19 total filings
· daily

DOE Energy Grants — March 06, 2026

General Matter, Inc. secured a $900M DOE obligation (potential $1.135B with options) for domestic HALEU UF6 production capacity, marking a major bullish signal for U.S. advanced nuclear fuel supply chain. The 10-year firm-fixed-price contract from 2026-2036 positions this small San Francisco firm for long-term revenue, though with execution risks from cost overruns and zero outlays to date. Investors in nuclear sectors gain a clear opportunity amid DOE's strategic push for HALEU independence.

1 total filings
· daily

General Federal Contracts — March 06, 2026

Federal contracts totaling $6.62B highlight bullish signals dominated by Lockheed Martin's $2.87B NASA space vehicle award (50%+ of value), alongside emerging $900M DOE HALEU production for General Matter and $724M VA healthcare IT for Optum/UnitedHealth. Healthcare IT and gov services show steady multi-year obligations (e.g., General Dynamics $146M CMS, Palantir $145M DHS), with long-term extensions to 2041 possible. Risks center on $0 outlays in 12 contracts and firm-fixed-price exposure, but options add $3B+ potential upside across portfolio.

19 total filings
· daily

All NASA Contracts — March 06, 2026

NASA's four historical contracts totaling $3.41B obligations (84% to Lockheed Martin) highlight trusted incumbents in space vehicle components and support, with bullish signals on Lockheed and Hamilton Sundstrand amid $268M unexercised options. Zero outlays and expired performance periods (2004-2013) across all signal data lags or completion, limiting near-term cash flow relevance. Investors gain insight into NASA's cost-plus preference for non-competitive awards to space primes, warranting parallels to current programs.

4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 06, 2026

Across 41 SEC filings dated March 6, 2026, primarily 8-Ks, 10-Ks, and proxies from diverse sectors mislabeled as Consumer Staples, overarching themes include FY2025 revenue declines in 6/12 reporting companies averaging -6% YoY (Krispy Kreme -8.6%, IMXI -8%, Mammoth -2.9%, ArcelorMittal -1.7%), widening net losses in biotechs (PMV +32% to $77.7M) offset by narrowing in services (Mammoth -65% to $63.8M via SG&A -83%), and active M&A (KEEMO control stake, Kratos $353M Orbit buy, Monroe-HRZN merger). Forward-looking catalysts shine with PMV NDA Q1 2027 (34% ORR), Clover GAAP profit 2026, Honeywell Aerospace spin Q3 2026, and Monroe pro forma NII rising to $1.24 by 2030. Capital allocation trends favor buybacks (Lakeland doubled to $60M) and debt for repurchases (O'Reilly $850M notes), but dilution risks loom from offerings (Modular $12M at premium) and conversions (Velo3D notes). Portfolio-level patterns reveal cash pressures (PMV cash -38% to $113M, runway Q2 2027) and litigation (Monroe suits), implying selective opportunities in clinical/M&A plays amid broader weakness. Sector implications point to turnaround potential via divestitures (Mammoth $150M cash, liquidity $157M) but vigilance on delistings (UAMY) and impairments (Krispy $356M goodwill).

25 high priority 16 medium 41 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 06, 2026

Across 87 filings from S&P 500 Industrials and adjacent sectors (heavily skewed to financials/banks at ~30%, biotechs/pharma ~15%, with true industrials like shipping, aerospace sparse), sentiment is mixed with 40% positive, 45% mixed, 15% negative; aggregate net income trends show 12/20 banks/financials up YoY (avg +35%, range 23-75%) driven by NII growth (avg +15%) and M&A, but offset by impairments/merger costs. Revenue growth strong in growth names (e.g., 25-39% YoY in Guidewire, Pattern Group, Granite Ridge) but margins compressed avg -100bps in 8/15 reporting cos amid higher opex/R&D. Key developments include M&A acceleration (Kratos Orbit $353M, Day One $2.5B acq at 68% premium, Honeywell Aerospace spin Q3 2026), proxy season ramp (20+ AGMs April 2026), and biotech catalysts (PMV NDA Q1 2027). Portfolio-level: Industrials show cap alloc stability (dividends flat/up), insider conviction low-visibility but positive CEO comp at Alphabet/Stanley; risks from credit deterioration (NPLs up in 4 banks) and cash burns (PMV -38% cash). Implications: Tactical longs in M&A banks/industrials, caution biotechs, watch Q1 earnings for NIM trends.

56 high priority 31 medium 87 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 06, 2026

In the S&P 500 Energy intelligence stream, Cheniere Energy's 8-K highlights a strategic Senior Notes offering due 2036 and 2056 for debt refinancing, capex, and growth opportunities, carrying high materiality (8/10) amid neutral sentiment. Howard Hughes Holdings' 8-K sets the 2026 AGM for June 4 with a record date of April 6, adjusting proposal deadlines to March 17 due to a >30-day shift from 2025, with low materiality (4/10) and neutral sentiment. No period-over-period comparisons (YoY/QoQ revenue, margins, or operational metrics) were disclosed across filings, limiting trend visibility. Absent insider trading activity, forward-looking guidance focuses on Cheniere's conditional debt raise and Howard Hughes' governance catalysts. Capital allocation leans toward Cheniere's debt-funded reinvestment vs. Howard Hughes' shareholder engagement timeline. Sector implications point to financing maneuvers supporting energy infrastructure amid no evident portfolio-level growth or compression patterns. Actionable focus: monitor Cheniere's offering execution for leverage shifts and Howard Hughes' proposal deadlines for governance risks.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 06, 2026

Across 347 filings from S&P 500 Financials and related entities, overarching themes include mixed financial performance with 12/25 10-Ks showing revenue growth averaging +25% YoY (e.g., Cohen & Co +454%, Chime +31%) but 8/25 reporting net losses widening (avg +40%, e.g., PMV Pharma +32%), margin compression in 7/15 cases (avg -150bps), and heavy M&A/SPAC activity (15 deals, e.g., Monroe Capital merger, Spring Valley fusion). Capital allocation favors dividends/buybacks in 9 firms (e.g., MarketWise +25% dividend, Cohen $0.95 special), while biotech/pharma (10 filings) highlight clinical progress amid cash burns (runway into 2027-2028). Insider activity shows low conviction with few buys but CEO transitions in 12 cases signaling potential shifts. Forward guidance mixed: 6 raises (e.g., MarketWise FY26 billings $300M), 4 cuts/lowers, building catalysts like AGMs (April) and earnings. Portfolio trends: Financials NIM stable/expanding in banks (e.g., Republic +20bps), but impairments/delisting risks in 8 small caps; relative outperformers like Cohen vs laggards like BP (-16% profit). Implications: Tactical buys in growth financials/M&A, caution on cash-burn biotechs.

237 high priority 110 medium 347 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 06, 2026

Across 22 filings in the USA S&P 500 Technology stream (though spanning finance, biotech, banks, and limited pure tech like Salesforce/NVIDIA), overarching themes include mixed financial performance with revenue/NII growth via M&A or clinical progress offset by rising expenses, NPAs, and dilutions; 7/22 showed YoY net income/loss improvements averaging 15% (e.g., biotechs narrowing losses 8-39%). Period-over-period trends highlight revenue acceleration in select names (IRADIMED +14% YoY, Camden NII +53% YoY) but portfolio declines (Oxford -3.4% YoY) and stable margins/NIM (IRADIMED gross 77% flat, banks ~4%). Insider activity limited to Form 4s (GENCO May25-Feb26 changes) and ownership updates (dMY to Mar6), signaling neutral conviction; capital allocation favors stable distributions/dividends (Oxford $0.105/share, Camden $0.42/qtr flat). Forward-looking catalysts cluster in biotechs (Immuneering 1H26 data, mid-2026 Ph3; Adial cash to H2 2026). Portfolio implications: Bullish turnaround in clinical biotechs, caution on banks' credit quality deterioration and dilutions; tech filings (Salesforce/NVIDIA) neutral with org/comp tweaks signaling continuity amid FY27 revenue focus.

16 high priority 6 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 06, 2026

Across 19 NASDAQ-100 related SEC filings from March 6, 2026, dominant themes include mixed financial performances in regional banks driven by mergers (e.g., First Community's Hometown acquisition completed Jan 23, 2026; Camden's Northway boosting NII +53% YoY), biotech firms narrowing net losses amid clinical progress (Immuneering's 64% OS rate vs 35% benchmark, Adial's -39% net loss improvement), and neutral capital market activities like debt shelf registrations (CIBC $20B) and offerings (CPKC $1.2B). Period-over-period trends show revenue growth in select names (IRADIMED +14% YoY, Altimmune +105% YoY) but expense pressures (G&A up across biotechs, noninterest expenses +38% at Camden), with ROE dips in banks (First Community -0.39pp, Camden -0.40pp). Positive catalysts cluster in biotech (Immuneering Phase 3 mid-2026, expanded data 1H2026), while tech filings highlight executive compensation alignment (Alphabet CEO $355M package, NVIDIA FY2027 variable plan). Portfolio-level patterns reveal bank M&A fueling asset growth (+20% Camden, +2% Muncy) but credit quality mixed (Muncy NPAs +18%), suggesting sector rotation opportunities into biotechs with extended cash runways (Immuneering to 2029). Overall, filings signal cautious optimism with 7/19 mixed sentiment, emphasizing monitoring Q1 2026 catalysts for alpha.

14 high priority 5 medium 19 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 06, 2026

Across 110 SEC filings from diverse US-listed firms (despite DJIA 30 focus, spanning banks, biotechs, SPACs, energy, and fintech), sentiment is predominantly mixed/neutral (70+ filings), with 25% positive on growth catalysts like revenue surges (avg +20-30% YoY in standouts like Grab, Via, Republic Bancorp) and clinical progress, but offset by cash burns, impairments, and exec churn. Period-over-period trends reveal banking sector resilience (e.g., NIM expansions in Republic +20bps, Northrim +NII 20%) amid rising NPLs (e.g., Home Bancorp 1.25% vs 0.50%), while biotechs show widened losses (PMV +32% YoY) but pipeline advances; energy firms mixed with Mammoth liquidity up to $158M post-divestitures. Capital allocation leans conservative (shelf registrations, buybacks like Dave $70M repurchase, Harley 10b5-1 plan), with SPACs/M&A active (ReserveOne, Vine Hill). Forward-looking catalysts cluster in Q1-Q2 2026 (PMV NDA, Nuvve BESS ops, Aptiv spin-off), signaling near-term volatility but alpha in undervalued growth names. Portfolio implication: Rotate to banks with NIM tailwinds and biotechs with derisked trials, hedge delisting/Nasdaq risks in small caps.

75 high priority 35 medium 110 total filings
· daily

US SEC Filings Daily Market Digest — March 06, 2026

Across 433 SEC filings dated March 6, 2026, for the period March 6, 2026, dominant themes include mixed 10-K results with revenue growth averaging +15% YoY in high-materiality filings (e.g., Chime +31%, Pattern Group +39%) offset by margin compression (-100 to -200 bps in 6/12 REITs/energy firms) and widened losses in biotech/REITs (e.g., Ares RE net loss doubled to $127M); M&A/SPAC activity surges with 15+ deals/announcements (e.g., Day One $2.5B acquisition, Quipt delisting post-arrangement); capital allocation favors dividends/buybacks (News Corp $1B program, MarketWise +25% dividend, 5 firms raised payouts); insider transitions neutral (e.g., Liberty CLO to advisor); delisting risks in 8 small caps (Traeger, Intensity regained but others flagged). Portfolio trends show REITs with NOI +12-21% but FFO drops (NewLake flat, Ares -82%), energy mixed (Granite production +28%, BP -12%), BDCs stable NAV/distributions. Forward guidance positive in 7/15 (MarketWise FY26 billings $300M, up from FY25 beat), bearish cuts in retail (Genesco FY27 sales flat). Implications: Opportunities in accretive M&A/guidance raises amid undervalued spin-offs; risks from delistings, covenant waivers (Nortech), impairments (Western Alliance $126M). Overall sentiment mixed (60% of 10-Ks), with action now on catalysts like March closings.

277 high priority 156 medium 433 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 06, 2026

Across 85 SEC filings from the S&P 500 Consumer Discretionary stream (broadly encompassing retail, automotive, hospitality, and adjacent sectors), overarching themes include mixed financial performance with 12/25 10-Ks showing YoY revenue growth averaging +18% (e.g., Chime +31%, Guidewire +25%) offset by declines in 8/25 averaging -15% (e.g., MarketWise -19.7%, Oxford Square portfolio -3.4%), margin compression in 10/20 reporting cos averaging -100bps amid expense growth, and robust capital returns via dividends (15 declarations, avg +10%) and buybacks (5 programs expanded/resumed). Critical developments feature accretive M&A (Chatham Lodging hotels at 10% cap rate adding 12% EBITDA, Kratos/Orbit $353M), spin-offs (Aptiv/Versigent by Apr 2026 with $1.7B dividend), and guidance raises (MarketWise FY26 billings to $300M, CFFO $50M). Portfolio-level patterns reveal hospitality strength (RevPAR +15% in acquisitions), subscription shifts to higher-ARPU (MarketWise ARPU $670), and bank-like efficiency gains (NII +15% avg in financial adjacents), signaling resilience in consumer spending pockets but caution on costs/delisting risks. Forward catalysts cluster in Apr-May 2026 (proxies, dividends, deal closes), positioning selective buys in undervalued growth names.

60 high priority 25 medium 85 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 06, 2026

Across 38 filings in the USA S&P 500 Healthcare intelligence stream (including tangential financials, biotechs, and providers), mixed sentiment dominates (15/38 filings), reflecting revenue/NII growth (avg 20% YoY in banks like Arrow +19.2%, Chime +31%) offset by rising expenses/losses (Chime net loss x40 to $1.01B, Jade +171% YoY) and asset quality slips (Flushing NPAs +25% YoY). Biotech standouts like Solid Biosciences ($240M raise, runway H1 2028), Jade ($336M cash post-$180M PIPE, Phase 1/2 data Q2 2026), and Absci (new CMO) signal pipeline conviction amid R&D surges. Healthcare provider Humana gears up for Apr 16 AGM with refreshed board (9/10 independent, age 73 retirement policy). Capital allocation shines with buyback expansions (Lakeland to $60M, Guidewire $148M repurchased), dividends (Broadridge $0.975/share), splits (HBIO 1:10 effective Mar 13), and financings (Core Scientific $500M loan to $1B accordion). Portfolio trends show NIM expansion (~+40bps avg in 7 banks to 3.6%), but NPAs rising in 4/6 banks (avg +18% YoY); April AGM cluster as key catalyst for governance votes. Implications: Favor growth biotechs/banks with strong liquidity, trim deteriorating asset quality names ahead of meetings.

27 high priority 11 medium 38 total filings